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1 Introduction
The Working Group ‘Overall Blood Supply Strategy with Re-
gard to Variant Creutzfeldt-Jakob Disease (vCJD)’ was formed 
in 2001 by request of the German Federal Ministry of Health 
in a letter dated January 26, 2001, consisting of staffs from the 
Paul-Ehrlich-Institut, the Robert Koch-Institut and the Federal 
Ministry of Health as well as external experts. On August 17, 
2001 the report prepared by this Working Group was submitted 
to the Ministry of Health and published after a discussion in the 
National Advisory Committee ‘Blood’ (Arbeitskreis Blut) as a 
brochure and online [1]. After reports were published in the 
UK in 2004 on the transmission of the vCJD pathogen by blood 
transfusion, the Working Group became active again, preparing 
an update of the report on April 13, 2004 which was published 
in scientific journals [2, 3]. One of the conclusions of this report 
was: ‘The secondary route of infection by blood could largely be 
stopped as soon as a suitable screening test becomes available. 
No such test is currently available nor is its availability foresee-
able. Providing resources for developing suitable test methods 
should therefore be treated with high priority.’ Early in 2008 
the Working Group has started meeting again with slightly dif-
ferent members in order to assess progress made in the field 
of diagnostics, particularly with regard to the development of 
screening assays for blood donations. Another task has been to 
critically evaluate the requirements regarding an implementa-
tion of such test assays in the present basic framework.
The previous report of the Working Group has only been pub-
lished a short time ago [2], therefore the present statement will 
not provide an extensive exploration of the whole set of vCJD 
problems again. Here we rather specifically discuss significant 
new aspects in the context of developing diagnostic assays. In 
order to illustrate the scope of the clinical difficulties, we give a 
brief survey on the epidemiology of vCJD and a presentation of 
how to clinically and diagnostically differentiate recently pub-
lished borderline cases. Because the most recent development 
of assays has predominantly targeted the detection of patholog-
ical prion protein (PrP), new aspects of the pathophysiological 
impact of prions and their detectability are discussed. 
Tests currently under development as well as recently pub-
lished methods are presented in brief, without aiming for com-
pleteness in this treatise or for an elaborate in-depth assess-
ment. The essential focus is rather on presenting and debating 
the general framework regarding the implementation of such 
assays. Relevant are the currently prevailing premises and the 
present regulation on the approval of the market access of 
screening tests for vCJD in Europe. Before the introduction of 
their widespread application in the screening of blood donors, 
the performance of the test assays must be thoroughly evalu-
ated regarding their sensitivity and particularly their specificity. 
Preconditions of such evaluation studies in the context of im-
plementing European regulations into the German legal system 
are discussed in detail. Ethical issues are particularly challeng-
ing, especially informing test persons / blood donors about a 
vCJD diagnosis that is still fatal, while a reliable confirmation 
test is lacking. At last, practical and technical requirements will 
be presented that must be considered on implementation. 
Without putting the general aim of effectively screening of 
blood donors for vCJD into question, the present report of the 
Working Group points out considerable difficulties when im-
plementing such assays under the prevailing preconditions. It 
should provide impetuses for the advancement of the handling 
of the assays by the regulatory bodies and for decision-mak-
ing regarding the pressing ethical issues. These considerations 
might also be valuable for other diseases that will come into the 
focus in the future. 
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2 Present Epidemiological Data on vCJD, Clinical  
and Diagnostic Differentiation from Sporadic CJD
In the early 1920s human spongiform encephalopathies were 
described by H.G. Creutzfeldt [4] and A. Jakob [5]. In the 1930s 
it could be demonstrated that scrapie, a spongiform encepha-
lopathy of sheep and goats, is a transmissible neurodegenera-
tive disease. Histological investigations of the brain of animals 
and humans who had contracted transmissible spongiform 
encephalopathy (TSE), using routine staining methods like 
hematoxylin/eosin staining, showed spongious alterations, loss 
of nerve cells, and in some cases amyloid accumulations. The 
degree of the morphological changes can vary in different re-
gions of the brain. Therefore the diagnostic standard procedure 
includes the identification of the pathogen PrPTSE in the brain. 
2.1  Epidemiology of vCJD
This form of the disease is associated etiologically and pathoge-
netically with bovine spongiform encephalopathy (BSE). So far, 
more than 200 cases of vCJD have been reported worldwide. 
These patients are considerably younger than those affected 
by the sporadic form of CJD, and the course of the disease is 
prolonged (table 1). Psychiatric abnormalities are predominant 
(mostly in the shape of depression or psychosis) that can last for 
several months without any neurological signs. Later there are 
painful dysesthesia and walking ataxia while dementia appears 
only late in the course of the disease. In vCJD, the abnormal 
PrP can usually be also detected in the peripheral lymphatic tis-
sues (appendix, tonsils, lymph nodes) (table 1). However, the 
abnormal PrP has also been found in the spleen and in muscle 
tissue in the sporadic form of CJD [6]. Transmissions of vCJD 
by blood transfusions were observed in the UK (detailed dis-
cussion in [2]). It can be considered as favorable that so far 
there have been no signs of an adaption of the pathogen after 
transmission via blood [7]. Table 2 gives a survey of the vCJD 
cases reported to date.
Based on a model calculation [9], in the previous report [2] the 
Working Group has come to the conclusion that in Germany, 
even in worst-case scenarios, blood transfusions would not sig-
nificantly promote the possible incidence of vCJD. Therefore, 
the report argued against an exclusion of transfusion recipients 
from donating blood. Mathematic modeling studies for the UK 
region [10] also assume that a perpetuation of vCJD is con-
ceivable, but improbable. According to actual calculations, the 
group at Imperial College in London does not consider blood 
transfusions to have any significant influence on the epidemiol-
ogy of vCJD [11]. 
2.2  Clinical and Pathological Classification, Phenotype  
Diversity of CJD
It is crucial to be able to differentiate vCJD which has eviden-
tially been transmitted by blood from other forms of human 
 vCJD sporadic CJD
Mean age at death 30 years 65 years
Mean duration of the disease 14 months 6 months
Clinical symptoms at the onset of  dysesthesia, behavioral changes memory disorder, ataxia
  disease
EEG non-typical 66% PSWCs
Detection of 14-3-3 protein in  50% 94%
  cerebrospinal fluid
Magnetic resonance tomography hyperintensities in the thalamus, hyperintensities in the 
 ‘pulvinar sign’ basal ganglia
Codon 129 genotype MM MM, MV, VV
Lymphatic system PrPTSE no PrPTSE
Neuropathologic characteristics ‘florid plaques’ variable, no ‘florid plaques’
PSWCs = Periodic sharp and slow wave complexes.
Table 1. Typical characteristics of vCJD com-
pared to sporadic CJD
Table 2. Presently known vCJD cases, as of August 19, 2008 [8]
Country Total number Secondary No residence
 of cases transmission  in UK 
  (blood) > 6 months
UK 166 3 (+ 1*) 
France  23  22
Republic of Ireland  4   2
Italy  1   1
USA  3   1
Canada  1  
Saudi Arabia  1   1
Japan  1   1
The Netherlands  2   2
Portugal  2   2
Spain  4   4
	 ---------------------------------------
Total  208 3 (+ 1 *) 36
*1 case of a probable transmission of vCJD, recipient has died from other 
causes.
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 Molecular  Clinical features Neuropathology PrP immunohistochemistry
 subtype
Frequent MM1/MV1 dementia, cortical  pronounced damage of the
  anopsy, myoclonia, short occipital cortex, PrP
  duration of disease accumulations of the
  (approximately 4 months) synaptic type
 MV2 ataxia, dementia,  focal damage of the cortex,
  extrapyramidal motion  amyloid (kuru) plaques,
  disorder, long duration of  focal plaque-like PrP
  disease (approximately  accumulations
  18 months) 
 VV2 ataxia at onset, dementia pronounced damage of the
  at a late stage, average subcortical structures as well
  duration of disease as the brainstem, often
  (approximately 7 months) spongiosis only located in
   the deeper cortical layers,
   plaque-like as well as
   perineuronal PrP
   accumulations
Rare MM2 thalamic  insomnia, dysautonomia,  atrophy of the thalamus
 (sFI) at a late stage ataxia and and the nucleus olivaris,
  cognitive disturbance lack of spongiosis possible
 MM2 cortical dementia for several months large confluent vacuoles 
   with perivacuolar PrP 
   accumulations
 VV1 dementia at onset, later  spongiosis, gliosis and loss
  ataxia and extrapyramidal  of innervation of the
  disorders cortical structures while
   omitting the brainstem and
   the cerebellum
vCJD MM2b psychiatric, dysaesthesia,  spongiosis, gliosis and loss 
  ataxia, later dementia of innervation as well as
   ‘florid’ plaques
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Phenotypical 
CJD characteristics
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TSE for which there are as yet no indications for a transmis-
sibility by blood. To illustrate this difficulty induced by the 
diversity in phenotype, some cases will be discussed here in 
detail. Recently, Mead et al. [12] have reported a CJD in a 39-
year-old female patient who first consulted a physician in Janu-
ary of 1999 because of visual disturbance. She then developed 
cognitive impairment, halting gait, motility disorder of the eye, 
dysarthria, stereotypical movements and myoclonia as well as 
finally progressive ataxia and dementia. 14 months after the 
onset of the disease the patient died. The codon 129 genotype 
was homozygous for valine. In this subtype (most often mo-
lecular VV2 subtype) ataxia is prominent while there are also 
signs of cognitive impairment, tonus abnormalities, and myo-
clonia. Typical characteristics are the lack of periodic sharp 
and slow wave complexes, as also happened in this patient, as 
well as the detection of the 14-3-3 proteins in the cerebrospi-
nal fluid. Magnetic resonance tomography (MRT) is compat-
ible with this subtype in which often a symmetrical affection 
of the basal ganglia without cortical involvement is found (un-
published data). A report in the journal New Scientist [13] cites 
the first author, Simon Mead, as follows: ‘The consensus is that 
it’s more likely sporadic, but we can’t conclude either way until 
further experiments are done.’ The overall course of disease is 
compatible with sporadic CJD, as observed in molecular VV2 
subtype (compare table 3), regarding the development of clini-
cal symptoms, the results of additional technical investigations, 
and the duration of the disease. 
Gambetti et al. [14] have recently described a novel degenera-
tive brain disease in humans that is associated with abnormal 
PrP. The disease occurred in patients of a mean age of 62 years 
and is clinically characterized by rapidly progredient cognitive 
disturbances as well as movement disorder. The clinical phase 
has a mean duration of 20 months. Brain tissue obtained by au-
topsy (10 patients) or by biopsy (1 patient) was investigated his-
tologically and showed spongiform degeneration, astrogliosis 
and in some of the cases ‘micro-plaque’-like accumulations of 
the PrP and, after immunohistochemical staining, pronounced 
granular accumulations of the PrP. On the biochemical level 
there was comparatively little abnormal PrP that was less high-
ly aggregated and the proteinase K(PK)-sensitive fraction of 
which was considerably larger than that in sporadic CJD. In ad-
dition, during enzymatic proteolysis the protein forms different 
protease-resistant cleavage products than those in the case of 
the well-known forms of CJD.
One year earlier a new subtype of CJD had been reported in 
Germany [15] that showed similarities to the above-mentioned 
cases described by Gambetti et al. [14]. The reports prompted 
a search for similar patients within the cohort of the German 
national reference center. So far, this search was unsuccessful.
Regardless of the above-described cases that are difficult to 
classify, the molecular classification of sporadic CJD is based 
on the codon 129 genotype of the PrP gene (homozygous for 
methionine (MM) or valine (VV), or heterozygous (MV)) and 
on the biochemical properties of the abnormal PrP (PrPTSE type 
1 or 2, differentiated by size and migration rate of the unglyco-
sylized PrP band in the immunoblot). The molecular subtypes 
of the disease are accompanied by distinct clinical and neu-
ropathological phenotypes of CJD (table 3).
MRT proves to be a diagnostic technique by which it is possible 
to differentiate individual CJD subtypes from each other and 

D
E
Fig. 1. a Patterns of lesions by MRT in sporadic CJD – differences in the molecular subtypes (weighting of diffusion). b Alterations in MRT in vCJD – 
 increased signal in the posterior thalamus (FLAIR [fluid attenuated inversion recovery] imaging). The image has kindly been provided by Dr D. Collie, 
Western General Hospital, Edinburgh, UK.
Transfus Med Hemother 2009;36:79–93Report of the Working Group ‘Overall  
Blood Supply Strategy with Regard to Variant  
Creutzfeldt-Jakob Disease (vCJD)’
83
from vCJD, even before death. In addition, it is instrumental in 
identifying atypical courses of the disease at a very early stage 
(fig. 1a, b).
2.3  Typing of PrPTSE
Cerebellar tissue of the patient that was homozygous for valine 
at codon 129 of the PRNP gene [12] was investigated by West-
ern Blot in order to type PrPTSE. Differences to well-known 
PrPTSE types of sporadic CJD isoforms (fig. 2) became apparent. 
The relative proportion and electrophoretic migration pattern 
of the di-, mono- and unglycosylated bands of the PK-digested 
PrPTSE were more similar to the PrPTSE type found in vCJD. In 
contrast to vCJD-associated PrPTSE, the addition of EDTA (a 
chelating agent binding copper and zinc ions) to the PK diges-
tion of the patient’s PrPTSE caused a further slight reduction in 
the molecular weight of the three protein bands. From the re-
sults of their Western Blot investigations the authors concluded 
that the pathological PrP of the patient investigated represents 
a novel PrPTSE type that is different from PrPTSE types so far 
observed in sporadic CJD cases. Furthermore the three-dimen-
sional structure differs from that displayed in vCJD-associated 
PrPTSE (from patients with MM at the PRNP codon 129). The 
authors classify the newly described PrPTSE type as ‘type 7’ in 
their classification system which is being developed over the 
past years. However, most experts prefer PrPTSE typing accord-
ing to Parchi et al. [16]. According to this system, there are two 
basic PrPTSE types associated with sporadic CJD and one PrPTSE 
type associated with vCJD. Parchi et al. [16] were able to show 
that even minimal variations of the experimental conditions 
(e.g. the pH value) in PK digestion have considerable impact 
on the size of the resulting PrPTSE fragments and may possibly 
generate artificial PrPTSE types. In order to be able to assess the 
results by Mead et al. [12], it would therefore be helpful if the 
investigations could be reproduced using the method by Parchi 
et al. [16] under exactly defined pH and buffer conditions. On 
the one hand, by such investigations the slight difference in 
molecular weight could be additionally corroborated which is 
observed after EDTA treatment compared to the vCJD-associ-
ated PrPTSE type. On the other hand, this might also lead to a 
better understanding of the results shown in figure 4c in [12]. In 
this figure the PrPTSE of the patient after EDTA treatment and 
PK conspicuously resembles PrPTSE type 3 rather than the new 
type 7 – unlike the one shown in lane 2 of figure 4b in [12]. 
It is not possible to deduce from the published Western Blot 
data of a single case whether the newly described PrPTSE type 
is in any way connected with the BSE agent. Only transmis-
sion experiments in transgenic or normal mice might shed more 
light on a more precise characterization of the agent strain, al-
lowing a continued sensitive epidemiological surveillance of the 
CJD trends. 
3 New Aspects of the Pathophysiology and the  
Diagnostics of Prions
In 1985 the PrP was identified as a gene product [17]. Since it is 
also found in healthy organisms, it is essential to be able to dif-
ferentiate between the normal or cellular PrP, called PrPC, and 
the pathogenic infectious isoform, called PrPTSE in this report. 
Both forms of PrP, PrPC and PrPTSE, display the same compo-
sition of amino acids [18] and glycosylation pattern as well as 
the same lipid anchor because both proteins are coded by the 
same gene. The differences between PrPC and PrPTSE lie in their 
structural and physicochemical properties that are assumed to 
be responsible for infectivity. These properties permit the de-
velopment of diagnostic assays for PrPTSE:
– Isolated PrPC is water soluble, whereas PrPTSE cannot be 
dissolved (without losing its infectivity).
– PrPC predominantly contains α-helices as its secondary 
structural element, whereas PrPTSE displays a high propor-
tion of β-sheet structures [19, 20]. Conversion of PrPC to 
PrPTSE renders the PrP infectious.
– PK treatment rapidly digests PrPC to oligopeptides, whereas 
in the case of PrPTSE PK treatment leads to the cleaving off 
of an N-terminal part of the PrP that is 68 amino acids in 
length. The cleavage site differs among the various prion 
strains and is located approximately between amino acid 
positions 87 and 107. The remaining molecule has a (strain-
specific) molecular weight of around 27–30 kDa which is 
the reason why it is also called PrP27-30. For hours it resists 
further PK digestion which is true for almost every prion 
strain. Therefore, the presence or absence of pathological 
PK-resistant PrPTSE in tissue homogenates can be detected 
by Western Blot, for example. The PK concentration in 
these experiments must be high enough for a complete di-
gestion of PrPC. 
Fig. 2. PrPTSE types 1 and 2 in isoforms of sporadic CJD in Western Blot.
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– High molecular PrPTSE aggregates can also be detected in 
infected tissues, e.g. as amyloid plaques. In tissue homoge-
nates aggregates can be separated from cellular, nonaggre-
gated PrPC, i.e. by centrifugation, and be enriched in the 
sediment. Treatment with e.g. phosphotungstic acid can in-
crease sedimentation [21]. 
Using immunohistochemistry, the misfolded PrPTSE is detect-
ed not only in a variety of plaques (kuru plaque, multicentric 
and florid plaques) but also in additional structures. The pre-
condition for an immunohistochemical detection of PrPTSE is 
a denaturing pretreatment of the tissue sections samples (e.g. 
formic acid or guanidinium thiocyanate treatment) so that cel-
lular PrPC can no longer be displayed. Additional treatment of 
the histological sections with PK can lead to an even more pro-
nounced visibility of PrPTSE. The immunohistochemical meth-
ods are based on antibodies against the PrP, either in the form 
of polyclonal sera or of monoclonal antibodies (MABs); the 
latter are almost exclusively used today. As mentioned above, 
the composition of amino acids and the glycosylation pattern of 
PrPC and PrPTSE are identical, therefore no immunological or 
inflammatory reactions can be detected, either during the in-
cubation stage or after clinical symptoms have developed. This 
explains the lack of serological detection methods like for other 
pathogens. Preferably knock-out mice that do not express PrP, 
so-called PrP0/0 mice, are used for the development of MABs. 
The best-known MABs are 3F4 [22] (reaction with human and 
hamster PrP), 13A5 [23] (reaction with hamster PrP) and 6H4 
[24] (reaction with human, bovine, ovine, mouse and hamster 
PrP). These MABs bind to both PrPC and (denatured) PrPTSE 
so that a differentiation between cellular and pathogenic iso-
forms of the PrP becomes possible only after using additional 
diagnostic methods, e.g. PK digestion of PrPC as used for the 
Western Blot. So far, only few MABs have been described that 
selectively recognize PrPTSE due to the reaction with a confor-
mational epitope. One of these is MAB 15B3 [24], a MAB of 
the IgM class. Above all, this MAB is used for precipitation 
and concentration of PrPTSE, while no additional properties of 
this MAB have yet been described. In the meantime, further 
conformation-specific MABs have been described [25–27]. Sev-
eral MABs that were described to be PrPTSE-specific apparently 
react with aggregated infectious and noninfectious PrP [28]. 
Binding of PrPTSE can be achieved by means of MABs coupled 
to ‘microbeads’; apparently MAB specificity does not play a 
role here [29]. 
In addition to detecting PrPs by antibody-binding reactions, the 
(differences in the) glycosylation pattern can be used for dis-
criminating prion strains according to their lectin-binding prop-
erties [30]. A PK treatment is required for such a differentiation 
because the binding to lectin in sporadic CJD is mainly detect-
able in the non-cleaved PrP while in vCJD the PK-treated PrP 
also shows a strong reaction. 
The correlation of infectivity with an immunohistochemical 
detection of PrPTSE in animal experiments (generally using in-
tracerebral application of brain homogenate or homogenates 
of other tissues such as spleen) has led to the conclusion that 
immunohistochemical proof of PrPTSE in fact confirms a TSE 
disease. Differentiation of the cellular (nonpathogenic) isoform 
PrPC from the (pathogenic) isoform PrPTSE is crucial since cur-
rently this represents the only diagnostic marker. It must be 
kept in mind that, in the case of a TSE disease, PrPTSE must be 
specifically identified in a background of PrPC present in a con-
centration that is several magnitudes higher. Several methods 
that are described below are under development which should 
allow differentiating of PrPC from PrPTSE for diagnostic pur-
poses. 
So far, the established methods for diagnosing a TSE disease 
like CJD or vCJD are based on either immunohistopathologi-
cal investigations or Western Blotting. In order to be able to 
identify PrPTSE by these methods, denaturing and/or proteo-
lytic cleavage of PrPC are required. The presently widely used 
conformation-dependent immunoassay (CDI) [21] represents 
the only method to specifically identify PrPTSE even in a back-
ground of high concentrations of PrPC. With this method even 
PK-sensitive PrPTSE could be detected in the brain of patients 
with sporadic CJD [31]. However, these methods are restricted 
to post-mortem diagnostics or to tissue biopsies. 
Resistance of pathogenic PrPTSE against PK digestion has long 
been known not to be absolute but rather dependent on the 
prion strain, too. For example, strain DROWSY (DY) is sensi-
tive to PK digestion, in contrast to other strains including strain 
HYPER (HY) [32]. DY and HY are prion strains that cause 
transmissible encephalopathy of the mink (TME) and that 
have been further passaged in hamsters. As has been observed 
in strain DY, infectivity of PrPTSE is not associated with PK re-
sistance of the PrP. Therefore some authors also use the terms 
sPrPTSE (PK-sensitive PrPTSE) and rPrPTSE (PK-resistant PrPTSE). 
Investigations of brain samples from patients with CJD have 
shown that more than 80% of total PrPTSE is PK-resistant [31]. 
Additional investigations in mice have confirmed an infectivity 
that is associated with PK-sensitive PrPTSE [33]. These investi-
gations have used prion strains in which only small amounts of 
PrPTSE could be demonstrated by immunohistochemistry. Here 
a high infectivity titer was found (more than 107 infectious units/
g of brain homogenate), but no PK-resistant PrPTSE. However, 
it must be taken into consideration that the sensitivity of the 
Western Blot was comparatively low: the detection limit was 25 
µg PrPTSE/g of wet weight.
In case PrPTSE isolated from brain homogenate is purified by 
differential centrifugation, and the supernatant is investigated 
for infectivity after high-speed centrifugation (220,000 × g for 
30 min), only a minimal amount (if any) of PrPTSE can be dem-
onstrated by Western Blot, but high infectivity titers. In this 
case also, infectivity seems to be associated mainly with PK-
sensitive PrPTSE (an at least 200- to 1,000-fold higher infectivity 
titer than expected from the biochemical signal (Western Blot) 
has been described [34]). It is noteworthy that the low PrPTSE 
signal in Western Blot could be precipitated quantitatively with 
phosphotungstic acid, together with the whole amount of infec-
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tivity of the sample. This precipitation step can also be usefully 
applied in precipitating PK-resistant PrPTSE [21, 35]. It remains 
to be clarified to what extent this PrP preparation, present in 
the high-speed centrifugation supernatant, consists (only) of 
low molecular PrPTSE aggregates showing a very high specific 
infectivity. For example, it was reported that oligomers consist-
ing of 14–28 PrPTSE molecules exhibit the highest infectivity. 
The molecular weight of these oligomers ranges between 300 
and 600 kDa, and their size is between 17 and 27 nm. Oligom-
ers consisting of as little as 5 PrPTSE molecules or less do not 
seem to be infectious [36].
Endogenous infectivity in the blood of experimentally infected 
animals can be demonstrated not only in the clinical but already 
in the preclinical stage of a TSE disease [37–41]. At least part 
of this infectivity is PK-sensitive [42]. An incubation of the en-
dogenous infectivity in plasma with different concentrations of 
PK (100 and 500 µg) reduces the infectivity titer from 20.6 in 
the control without PK down to 8.4 and 5.2 infectious units/ml, 
respectively. However, it must be stated that the PK concen-
trations investigated were insufficient for a complete digestion 
of plasma proteins. Therefore, it cannot be excluded that a PK 
concentration sufficiently high for a complete proteolysis of 
plasma proteins would also have completely digested the infec-
tivity in the plasma samples. 
As mentioned above, to some extent infectivity can be PK-sen-
sitive. Therefore, it must be pointed out that diagnostic assays 
using PK digestion for differentiation might miss part of the in-
fectious PrPTSE and might thus prevent correct diagnostic con-
clusions.
4 Development of Diagnostic Assays
In statements regarding measures to prevent the transmission 
of vCJD via blood and blood products, various countries have 
addressed the necessity of developing diagnostic assays for the 
identification of vCJD infectivity in the blood. For example, the 
Working Group ‘Overall Blood Supply Strategy with Regard to 
Variant Creutzfeldt-Jakob Disease (vCJD)’ in their statement 
dated April 13, 2006 [2] pointed out that the development of 
screening assays was one of the key issues in preventing pos-
sible transmissions of vCJD by blood products, and in initiating 
therapeutic measures – supposed they would be available – at 
an early stage of infection. If a direct identification of vCJD-in-
fected blood donors by screening assays was to become possible 
already in the incubation period, testing of donations would be 
particularly superior to any indirect measures that lack specifi-
city, such as the prophylactic exclusion of groups of donors with 
an elevated risk in their history. 
The major difficulty in developing such assays is the very low 
concentration of PrPTSE that is to be expected, in a background 
of the physiological PrPC that is present at an approximately 
10,000-fold surplus. The analytical sensitivity of screening as-
says that seem to be appropriate for the detection of PrPTSE in 
serum or plasma must be far lower than 1 pg/ml PrPTSE [2]. As-
suming that in an infected brain one infectious unit corresponds 
to approximately 0.01–1.0 µg, the required sensitivity of the 
assay would have to correspond to approximately 1–100 nl of a 
10% brain homogenate [43]. Additional requirements are high 
specificity, robustness as well as applicability in blood donation 
testing. 
The UK National Institute for Biological Standards and Control 
(NIBSC) provides a plasma panel containing variable amounts 
of infectious and noninfectious material from the brain or spleen 
of patients with vCJD (NIBSC CJD Research Centre, Plasma 
Panel, Reference code NHPM0/0015: Normal Human Plasma 
spiked with vCJD Ctrl Brain/Spleen, 22 tubes, concentration 
range). This as well as other panels have already been used in 
a comparative assessment of tests under development. In 2007 
Phil Minor has reported the results of an external quality as-
sessment involving seven laboratories using eight test assays. 
Four out of eight assays were able to detect ≤100 nl of a 10% 
brain homogenate containing the vCJD agent while three other 
assays detected <300 nl [43]. At a hearing of the DG Enterprise 
(Directorate General Enterprise and Industry) on October 27, 
2007 in Brussels a company announced that they were aiming 
to obtain the CE marking for a test assay still in 2008 [44].
In the context of an epidemiological investigation, the British 
health authorities stated on February 6, 2007 their intention to 
test 60,000 plasma samples [45]. Companies were requested to 
provide assays for these investigations. As a first step in select-
ing an assay for these investigations, the comparative assess-
ment of a plasma panel was performed by an independent labo-
ratory. While the comparative assessment has been finished, 
the epidemiological investigation has not yet started.
Because the development of diagnostic assays is progressing 
considerably, it has become necessary to clearly determine 
which specific requirements should be made on a test able to 
detect vCJD in blood and which materials could be provided to 
characterize such an assay.
Currently various diagnostic assays are being developed, using 
different approaches. Such methods are based e.g. on bind-
ing to specific ligands, on the application of antibodies, on the 
detection or induction of conformation changes as well as on 
PCR-like protein amplification. Some of these assays will be 
briefly presented in the following.
4.1  Conformation-Dependent Immunoassay (CDI)
Detection of PrPTSE by CDI (originating from S. Prusiner’s lab-
oratory) uses the approach of ‘epitope exposure’ [21, 31]: de-
fined epitopes that are at first inaccessible in the native PrPTSE 
are exposed by denaturation, followed by detection using a 
Europium-labeled antibody. Last year, at the conference ‘Prion 
2007’ in Edinburgh, J. Safar reported that this assay was able 
to detect PrPTSE in LDL (low density lipoprotein) fractions in 
plasma from patients with sporadic CJD. For 20 patients with 
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sCJD a sensitivity of the assay of 90% was found, while spe-
cificity was 98 and 95% using control samples from 103 normal 
blood donors and from 20 donors with dementia of other etiol-
ogy (like e.g. Alzheimer’s disease), respectively. 
4.2  Misfolded Protein Diagnostic (MPD) Assay
To specifically detect PrPTSE, this assay employs a pyrene-la-
beled palindromic sequence of prion peptides. As their charac-
teristic molecular structural element, pyrene and its derivatives 
possess a conjugated aromatic system of four fused benzene 
rings. They are used among other things as dyes and as molecu-
lar probes in fluorescence spectroscopy. A palindrome is a row 
of signs that, on reading forward as well as backward, result in 
the same sequence of signs. The peptide employed in the MPD 
assay undergoes a cascade of coil to β-sheet conversion in the 
presence of PrPTSE, accompanied by a measurable fluorescence 
shift of the dye. In a blinded study using the MPD assay it was 
possible to detect PrPTSE in the plasma of 5 patients with spo-
radic CJD while the assay gave negative results for the plasma 
from 5 normal donors [46]. 
4.3  Epitope Protection Assay
This assay is based on the modification of amino acids of the 
PrP by reaction with free radicals that are released by chemi-
cal reactions. This results in the destruction of specific epitopes 
on the surface that can no longer be recognized by antibod-
ies. Because the pathogenic PrPTSE is present in an aggregated 
form, part of the protein is protected against reaction with free 
radicals. Epitopes are thus preserved that can then react with 
monoclonal antibodies which allows to detect PrPTSE after dis-
integration of the aggregates in the immunoassay. The assay 
employs magnetic beads loaded with antibodies and is sup-
posed to be able to detect less than 10 fg recombinant PrPTSE 
in the sample. 
4.4  PMCA-Based Detection of PrPTSE
In 2001 Soto and colleagues [47] have published the ‘Protein 
Misfolding Cyclic Amplification’ (PMCA) as a method to am-
plify pathologically aggregated PrP in vitro. PrPTSE, the disease-
associated form of the PrP, is first incubated in a surplus of 
normal, nonaggregated PrPC. Seeded nucleus-induced polym-
erization integrates PrP into available PrPTSE aggregates, caus-
ing them to virtually ‘grow’. Using sonication, these enlarged 
PrPTSE aggregates are then fragmented into smaller parts which 
in turn can function again as ‘matrices’ or ‘nuclei’ in another 
PMCA cycle. It is unclear whether such reaction products are 
infectious; in case they are, special safety measures would be 
required.
Recently, Atarashi et al. [48, 49] have reported to have en-
hanced the PMCA technique resulting in the QUIC  Assay 
which is supposed to allow a considerably more rapid and fea-
sible detection of PrPTSE than conventional PMCA methods. 
By employing recombinant PrP as a substrate, incubating the 
samples at elevated temperatures and shaking (instead of soni-
cation), the procedure is supposed to enable the detection of 
approximately 1 infectious unit in 24 h. The QUIC Assay was 
able to discriminate between scrapie-infected and uninfected 
hamsters using cerebrospinal fluid. The procedure has only 
been described for the hamster model so far.
4.5  Amyloid Seeding Assay (ASA)
Colby et al. [50] have developed a method to induce polymeri-
zation of recombinant PrP into amyloid fibrils by using PrPTSE 
aggregates as seeds. The term ‘amyloid’ designates protein ac-
cumulations of diverse origin that can be detected in the light 
microscope and that share the following characteristics: i) fi-
brillary ultrastructure, ii) affinity to the dye Congo red, and iii) 
characteristic β-sheet structures. The PrP amyloid produced in 
the ASA is detected by binding to the dye thioflavin T (that 
shows a fluorescence shift after the binding). With the aid of 
ASA it was possible to detect PrPTSE in diluted brain homoge-
nates from patients with sporadic CJD as well as in a variety 
of prion strains passaged in both mice and hamsters. Conserva-
tively estimated, the detection limit for PrPTSE in the ASA is 
supposed to be ≤1 fg, and test results are obtained within 24 h. 
4.6  Cell Panel Assay
Mahal et al. [51] described a cell culture assay with four cell 
lines that have varying susceptibility to infections with mouse-
adapted prion strains RML, 22L, Me7 (scrapie-associated 
agents) and 301C (BSE-associated agent). The assay allows to 
detect and discriminate these prion strains within 2 weeks. As 
yet, the application of the Cell Panel Assay is relatively limited 
because the susceptibility of the cell lines is confined to murine 
prion strains. 
4.7  Detection of Prions in Organotypic Brain Slice Cultures
Falsig et al. [52] used the so-called ‘POSCA’ (prion organo-
typic slice culture assay) for ex vivo replication and titration of 
the prions that are to be detected. Organotypic slices from the 
cerebellum of PrP-overexpressing tga20 mice were incubated 
in cultures for extended periods of time. 35 days after contact 
with prion-containing material (scrapieRML brain homogenate), 
mouse cerebellar slices had amplified PrPTSE >105-fold, as 
shown by Western Blot. Other prion strains (79A, 139A, Me7 
(scrapie-associated agents) and 301C (BSE-associated agent)) 
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also showed PrPTSE amplification using POSCA, but with vari-
able efficiency. However, for mouse-adapted agents of the 
chronic wasting disease (CWD) as well as other defined scrapie 
strains, tga20-POSCA gave negative results. The range of ap-
plication of the assay might be considerably expanded because 
organotypic brain slice cultures can be established from mice 
with the required genotypes as well as from a variety of differ-
ent host species. 
4.8  Atomic Dielectric Resonance Spectroscopy (ADRS)
Fagge et al. [53] have used ADRS to determine dielectric char-
acteristics of sample material with the help of radio/micro waves 
in order to analyze blood samples from CJD and vCJD patients 
and identify characteristic ‘ADR signatures’ in the blood. In a 
preliminary study using unblinded samples from normal blood 
donors and from patients with vCJD, sCJD as well as other 
neurological diseases, initially group-specific ADRS properties 
were determined, and statistic analysis systems were trained to 
classify unknown samples. In a subsequent study employing 
these analysis systems it was possible to correctly classify ten 
blinded samples (four of them vCJD, three sCJD, three other 
neurological diseases). The investigations show that on the mo-
lecular level differences between the blood samples from the 
different groups of donors can be identified, but these differ-
ences cannot be specified. Moreover, the authors point out that 
it will be necessary to further verify their results in considerably 
larger studies.
5 Evaluation and Market Access of vCJD Screening 
Assays 
5.1  Regulation of in vitro Diagnostic Medical Devices in  
Europe
It is one of the aims of the development of specific vCJD assays 
to identify potential carriers of vCJD already by blood screen-
ing on the occasion of blood donation and to eliminate their 
donation in time. Thus these assays would be applied similar 
to virus screening tests already widely in use by blood donation 
services, e.g. anti-HIV-1/-2 screening assays.
In Europe virus diagnostics for infections with HIV, HBV, 
HCV and HTLV, so-called high-risk products, are regulated 
considerably more stringently than other diagnostics, due to the 
in vitro diagnostic medical devices (IVDs) directive [54]. The 
reasons behind this classification are the severe consequences 
of false test results, for those concerned as well as for third par-
ties, for example in the case of transmission of these viruses by 
blood transfusion to other persons due to false-negative test re-
sults of the blood donor. Regarding those IVDs not classified 
as high-risk products, the manufacturers are given as much of 
a free hand as possible to assess the state of the art on their 
own responsibility and to declare by CE marking the market-
ability of the products within the Common Market of Europe. 
In the case of high-risk products a thorough examination by an 
independent institution (Notified Body) is foreseen. Specific 
quality requirements, the Common Technical Specifications 
(CTS), must be met. In addition, before reaching the European 
market, the product batches are also counterchecked in an in-
dependent laboratory (batch release testing). 
Regarding the risk potential, diagnostic assays for vCJD intend-
ed to be used in the blood service will have to take a position 
similar to anti-HIV-1/-2 screening assays: Release or exclusion 
of a blood donation is directly dependent on each test result. 
Any false-negative test results might have severe consequences 
for recipients of blood transfusions. Any reactive and poten-
tially false-positive test results would require extensive inves-
tigations to clarify these results, as far as this was possible at all 
for vCJD diagnostic assays. Furthermore, reactive test results 
would represent a heavy psychological burden for the donor. It 
has to be mentioned that the IVD directive has been written at 
a time when neither the disease vCJD was known nor diagnos-
tic assays for vCJD-infected individuals were conceivable. 
A formal application to the European Commission is required 
in order to include new diagnostic assays into list A (high-risk 
products), as has been explained in detail in article 14 of the 
directive 98/79/EG. After some preliminary discussions, it was 
left to UK – being the member state most affected by vCJD 
– to file an application to include vCJD diagnostic assays into 
list A, annex 2, of the IVD directive. Such an application was 
filed in 2007 and is supported by several other member states, 
among them Germany and France. At a public hearing in Brus-
sels dated October 26, 2007, such a classification of vCJD assays 
was also supported by the European IVD manufacturing indus-
try (European Diagnostic Manufacturers Association; EDMA) 
and the European Medicines Agency (EMEA). As long as list 
A of the IVD directive has not been expanded – the application 
filed for this according to article 14 [54] can still take years until 
an official decision is made – vCJD assays can be CE-marked 
without special requirements and marketed in the Common 
Market, even for application in blood donation screening. This 
widely unregulated situation is very alarming.
On the occasion of the public hearing in Brussels it became also 
apparent that the development of CTS regarding vCJD assays 
will be urgently needed. A significant step would have to be 
experimental assessment of the assays using well-character-
ized samples with known vCJD infectivity. This endeavor ap-
pears to be quite difficult because such reference samples for 
vCJD are not available due to the low number of cases. In the 
meantime efforts have been made to collect the scant sample 
material and to systematically make it available (see below). It 
will be inevitable to also include other sample material, such 
as samples from TSE animal models, in an initial validation of 
diagnostic assays for the detection of vCJD in human blood. 
Anyway, a simple transfer of those CTS already established for 
current virus screening assays to the newly developed vCJD 
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assays is not possible for several reasons. Another problem is 
the required testing of clinical samples in respect of sensitivity. 
For example, at least 400 different positive patient samples are 
mandatory for a sensitivity trial of the various virus screening 
assays, without missing any sample. Certainly this criterion is 
not applicable at present to vCJD assays because such sample 
numbers are not available. 
Investigating the specificity of such assays would also be dif-
ficult. A minimal specificity of 99.5% is required in the CTS 
for virus screening assays. The specificity of blood screening 
assays has to be determined using samples from 5,000 blood 
donors. By definition, an investigation has a false-positive re-
sult if an initially reactive test is repeatedly reactive using the 
same sample and if comparable control or confirmation tests 
have negative results. Also there must be no further indication 
of a corresponding infection (e.g. clinical symptoms) for the 
person concerned. To implement a novel diagnostic assay with-
out a control or confirmation test would imply that it would be 
impossible to differentiate false-positive from correct true-posi-
tive test results in a population that is not well characterized. 
Therefore, it is almost impossible at present to estimate the 
specificity of a vCJD assay. CTS further require the investiga-
tion of samples from hospitalized patients and samples with 
potentially cross-reacting components. Regarding vCJD assays, 
an investigation of individuals with neurological diseases for 
whom vCJD has been ruled out seems to be indicated. It has 
to be discussed further to what extent the etiological agents of 
other human TSE diseases may or even should cross-react. 
In the UK a committee composed of international experts has 
been appointed at NIBSC (vCJD Repository Oversight Com-
mittee) that develops criteria for making available to manufac-
turers of diagnostic assays the samples registered and stored in 
the ‘vCJD repository’ of NIBSC. The Paul-Ehrlich-Institut is 
part of the Oversight Committee and has decided to add sam-
ples from vCJD-infected primates that were collected in the 
context of an EU research project at the Paul-Ehrlich-Institut 
to this vCJD repository at NIBSC. Thus IVD manufacturers 
are offered a contact point and a procedure to obtain appro-
priate samples that are provided under generally accepted con-
ditions. NIBSC has already asked one manufacturer to make 
their diagnostic assay available for validation investigations 
[55]. Future CTS for vCJD assays will certainly have to also be 
coordinated with this policy. 
Regardless of the obvious difficulties, the attempt must be 
made to define mandatory quality criteria also for vCJD assays, 
whether in the form of CTS or otherwise. 
5.2  Legal and Ethical Aspects Regarding the Development 
and Application of Diagnostic Assays 
Performance evaluation studies involving test persons and pa-
tients are necessary for an evaluation of novel IVDs. In the case 
of validating vCJD screening assays this would also include the 
testing of blood donors. Many difficult questions arise, not 
only in the context of these studies but also on implementing 
such assays into routine screening of blood donors. The set of 
problems under scrutiny here is particularly complex. The par-
ticular situation in Germany including the basic legal aspects 
and ethical implications (sources of information regarding the 
regulations and legislation are listed there) is discussed in de-
tail in ‘Legal and Ethical Aspects Regarding the Development 
and Application of Screening Assays to Detect vCJD Infec-
tions’ (see online supplemental material at www.karger.com/
doi/10.1159/000188082).
In summary the following should be noted:
a) Performance evaluations of IVDs are aimed at obtaining 
CE certification and thus marketability of such medicinal 
devices in the EU. Their purpose is to determine the safety 
and qualification of the IVDs for the intended application. 
b) In order to ensure health protection for the population, 
in accordance with section 5 paragraph 1 Transfusion Act 
(Transfusionsgesetz; TFG), IVDs that allow the detection of 
grave and epidemiologically significant infectious diseases 
have to be employed to determine the eligibility of a person 
to donate blood. This applies under the precondition that 
IVDs are technically safe and suitable and that sufficient 
safety cannot be reached by other measures (e.g. donor ex-
clusion). However, in view of the presently known epide-
miological situation of vCJD in Germany, in view of only 
four confirmed transmissions by blood transfusion in the 
UK and in view of the difficulties described above regard-
ing performance evaluation, the implementation of vCJD 
diagnostic assays appears to be inadvisable at present. 
c) The performance evaluation study of an IVD for the de-
tection of vCJD infections regularly requires the informed 
consent of the participant, see § 24 paragraph 1 Medical 
Devices Act (Medizinproduktegesetz; MPG). The only con-
ceivable exception would be the investigation of factually 
anonymized samples from those individuals who are not at 
the same time donors in terms of the TFG, who are not sus-
pected to carry any other disease and whose blood samples 
were taken for other reasons than performance evaluation 
studies. 
d) Already in the case of a ‘justifiable suspicion’ of a donor 
to be infected with vCJD, the physician responsible is ob-
ligated to eliminate the donation, to trace and inform as 
well as examine any recipients and to inform the authori-
ties responsible, unless there is a reasonable assumption of 
its probably being a false-positive result (see also section 19 
paragraph 1 sentence 1 and sentences 6–8 as well as section 
3 TFG). In view of the largely unknown epidemiology of 
the vCJD infection, the latter assumption cannot be justi-
fied by statistical considerations alone. Rather it has to use 
as definitive guidance the sensitivity and specificity (to be 
supported by performance evaluation studies) as well as 
technical feasibility of the assays to be developed for de-
tecting a vCJD infection. On the condition that there was 
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a vCJD assay available, the fact alone that as yet there was 
no assay for confirmation or exclusion of a reactive vCJD 
screening test result, would be no sufficient reason to ex-
clude a ‘justifiable suspicion’ for a vCJD infection in terms 
of the TFG, section19 paragraph 1 sentence 1.
e) In investigations carried out in the context of or on the 
occasion of blood donation, employing an IVD to detect 
a vCJD infection, a positive result implies the duty of the 
physician responsible to inform and counsel the donor on 
this fact, provided that it must be assumed that the IVD has 
to be regarded as able to ‘confirm’ a vCJD infection (see 
also TFG, section 19 paragraph 1 sentence 4). In this regard 
it firstly depends on the respective state of development of 
the IVD whether it can be regarded as suitable for allowing 
a confirmed diagnosis of a vCJD infection, even at this early 
stage during performance evaluation studies. According to 
the current state of scientific knowledge, this cannot yet be 
answered affirmatively in view of the vCJD diagnostic as-
says under development. 
f) In case a positive test result is disclosed, the person con-
cerned must receive counseling and advice by a physician, 
see also TFG, section 19 paragraph 1 sentence 5. But it must 
be taken into account that currently no diagnostic method is 
established to confirm a positive screening test result ante 
mortem and no therapy to treat or cure the terminal vCJD 
disease. 
g) On request, participants in a performance evaluation study 
regarding an IVD for detecting vCJD must be informed 
about the test results, see sections 19 and 34 Federal Data 
Protection Law (Bundesdatenschutzgesetz; BDSG). In this 
connection they must be informed before and after partici-
pation that a positive test result does not mean in every case 
that they are infected with vCJD and, even if they should 
actually be infected, that no statement can be made regard-
ing the question of whether the disease will become symp-
tomatic. Furthermore they should be offered counsel and 
help.
h) The application of screening assays for detecting vCJD in-
fections may have a negative effect on the general willing-
ness to donate blood, but this fact is no adequate reason 
to interfere with performance evaluation studies or with 
the implementation of an IVD to detect vCJD infections 
in blood donations, at any rate unless such an infection of 
blood donors and in blood products can be excluded by 
other diagnostic methods. 
i) Before performance evaluation studies of an IVD can be 
started, ethics boards must be involved either because of 
section 24 paragraph 1 in conjunction with section 20 para-
graphs 7 and 8 of the MPG and/or because of legal guide-
lines for physicians (see section 15 of the Medical Associa-
tion’s professional code of conduct).
6 General Conditions and Problems Expected to Arise 
on Implementation of vCJD Screening Assays
6.1  Sensitivity
Due to the scarcity of human samples, the stage of development 
of the diagnostic assays so far does not allow any statement on 
their sensitivity regarding detection of vCJD in the preclini-
cal stage. A negative result does not rule out an infection with 
vCJD. 
Considering the epidemiological situation in Germany which is 
presently characterized by a prevalence and incidence too low 
to be measured, it is impossible in the current situation to quan-
tify the increase of safety that is to be gained by screening for 
vCJD in terms of avoiding transfusion-transmitted vCJD. 
6.2  Specificity
Up to now available investigations using very small sample 
numbers indicate an unsatisfactory specificity. With all due 
caution one has to assume a rate of false-positive results of ap-
proximately 2%. Only by extensive studies using samples from 
blood donors will it be possible to establish a test-immanent 
specificity of the various assays. The medico-legal difficulties 
involved have been discussed above under section 5.
On behalf of a maximal safety for transfusion recipients, all 
donations showing reactive screening results would have to be 
destroyed and actually, as a consequence in the absence of con-
firmation tests, donors would have to be excluded from further 
blood donation. Moreover, to be consistent, a look-back proce-
dure would have to be initiated covering the entire donor histo-
ry as far back as 1980, and recipients of blood products as well 
as the plasma fractionation industry would have to be notified. 
In Germany in 2006 4,595,484 homologous whole blood dona-
tions and 1,731,921 plasma and thrombocyte apheresis dona-
tions were collected [56]. On average, whole-blood donors do-
nate every 6 months and apheresis donors once every month 
[2]. Based on an assumed rate of 2% false-positive results, at 
least in the first year after implementation of the test, approxi-
mately 92,000 whole-blood donors and up to 35,000 apheresis 
donors would have to be informed and excluded from further 
donations. Because repeat donors tend to donate regularly for 
years, the effort regarding look-back measures would be ex-
traordinary. The same applies to apheresis donors who donate 
very frequently and to plasma donors whose plasma for frac-
tionation is part of a plasma pool used for the manufacture of 
various plasma products.
6.3  Ethical Problems
Based on the actual epidemiological situation in Germany, it 
can be assumed that in fact almost none of the reactive results 
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would indicate a real preclinical vCJD. If donors as well as 
recipients of blood products produced earlier were informed 
about a very vague suspicion concerning a fatal disease that 
can neither be ultimately ruled out nor treated, a considerable 
psychological strain for those concerned would be caused that 
might have conceivable respective consequences, potentially 
culminating in suicide. 
Those concerned will ask a number of questions:
– When did the infection happen?
– How likely is my becoming ill?
– When will the disease break out, what are its symptoms?
– In case I was infectious, how can I transmit the agent?
– Do I have to inform my partner?
– Is a sexual transmission possible?
–  May I become pregnant, and how high is the risk of trans-
mission to the fetus?
–  If my blood is infectious, what do I have to do if I suffer an 
injury?
Based on the current state of knowledge, one would give sooth-
ing answers, but this would be in stark contrast to the measures 
to be initiated for the sake of consistency. 
Donors concerned (as well as recipients of blood components 
from these donors) would have to be advised to stop to donate 
blood, plasma, sperm, tissues or organs in the future. On the oc-
casion of every medical, surgical and dental intervention they 
would have to inform about their existing potential infectiv-
ity. Medical institutions would have to implement considerably 
more measures than before to minimize the risk of these patients 
to transmit pathogenic prions. In the UK several hundred hemo-
philiacs had been treated with coagulation products that were 
possibly contaminated with the vCJD agent. Experiences from 
these persons in the UK showed that for example it had become 
very difficult for these patients to receive dental treatment. 
Medical personnel with a reactive result in a vCJD test would 
have to stop performing certain parts of the job that are asso-
ciated with a higher risk of injury (similar to those individuals 
infected with hepatitis B or hepatitis C). 
Apart from family distress and depression, grave disadvantages 
must be taken into consideration, e.g. when contracting life in-
surance, vocational disability insurance or private health insur-
ance, because of a diagnostic result which is highly likely to be 
false in diagnosing preclinical vCJD. 
Apart from this, on implementing such diagnostic assays, ad-
equately trained medical and pastoral personnel will have to be 
available to carry out information and counseling of the donors 
concerned, which is required in accordance with the TFG.
One way of overcoming this set of problems would be, on ac-
count of currently unreliable data, to generally not inform in-
dividuals about a reactive result on performing a vCJD test. 
However, if a vCJD case should actually be diagnosed later on, 
or even another person be infected or have been infected in the 
past, accusations of violating due diligence are to be expected.
On the other hand, the specifications of the TFG must be 
observed (see also section 5). A justifiable suspicion for an 
infection with vCJD based on the test results will initiate a 
look-back procedure in addition to destroying the actual do-
nation. However, the donor has to be informed only after a 
confirmed diagnosis of a symptomatic disease or an infection, 
even though further donations will most probably become use-
less on account of their inherent albeit small risk. Furthermore, 
the donor is often suspended electronically and will be deferred 
without previous explanation, e.g. on the occasion of a compu-
ter-based mobile data entry. Under the present legal position 
in Germany, only if the donor actively requests an explanation 
of the reason for deferral, the blood service is allowed to exten-
sively inform him/her about a justifiable suspicion. 
In this situation, legally accepted definitions of both a justifiable 
suspicion and a confirmed diagnosis of vCJD must already be 
developed before performance evaluation and before, during 
and after implementation of a new diagnostic assay. These defi-
nitions are to be continuously updated according to the state of 
knowledge.
In order to establish definite rules for all concerned and to 
prevent subsequent criminal conviction, a consensus must be 
reached on the legal, political as well as social level regarding 
the resulting direct and indirect consequences and measures.
6.4  Restrictions on Supply
Based on an average frequency of donating whole blood of 
once every 6 months and of donating by apheresis of once 
every month [2] and also including the numbers mentioned 
under section 6.2, in 2006, approximately 2.3 million persons 
donated whole blood and 144,000 persons blood components 
or intermediates obtained by apheresis.
Assuming again the scenario of 2% false-positive results, in the 
first 12 months after test implementation, approximately 46,000 
whole blood and 2,900 apheresis donations would be excluded 
from further blood donations. Thus the supply would be re-
duced by approximatley 92,000 erythrocyte concentrates and 
23,000 l of plasma obtained from whole blood donations and 
approximately 35,000 blood components obtained by apheresis 
techniques. A further deterioration in supply is to be expected, 
especially regarding erythrocytes that at this stage have already 
begun to fail to meet demands. 
Furthermore, it must be taken into consideration that 3 new do-
nors have to be recruited within 12 months to replace 1 donor 
regularly donating whole blood [2]. To keep up the present sup-
ply, approximately 140,000 persons have to be newly motivated 
to donate blood.
In the context of the increasingly tight blood supply situation in 
Germany, a retraction of donors of the magnitude mentioned 
above would inevitably result in further bottleneck situations in 
supply, in the worst-case scenario leading to a collapsed service. 
This also applies in cases when an information of the donor is 
abandoned and just the respective donation is not released for 
use.
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Deficits in plasma donations – and to a lesser extent in plasma 
for fractionation produced from whole blood – would lead to 
serious problems in supplying patients with immunoglobulins, 
coagulation factors, and other medical drugs produced from 
plasma. Whether imported plasma that was tested negative for 
vCJD became available for compensation is doubtful because 
donor retractions related to a test implementation would lead 
to a further shortage of plasma as a resource also on an inter-
national level. 
6.5  Feasibility
Particularly for large blood services, it will only be possible to 
screen for prions if high-throughput automats are available. On 
account of the necessary release of blood components within 24 
h or less after collection, the mere duration of the test should 
not be significantly longer than 4 h. It is impossible to delay the 
release for several days, especially for short-lived preparations 
like thrombocyte concentrates that, adapted for patients, have 
to be applied urgently or vitally important. Presently no suit-
able automated systems and corresponding reagents are avail-
able for these requirements. Until a minimum test specificity of 
99.5% is reached for the assays (minimum requirement of the 
common technical specifications regarding infection serological 
assays), an implementation of an assay will be problematic as 
a result of the difficulties described in section 6.2. A specificity 
that is even higher would be preferable.
In addition, the legislator has to generate regulations permitting 
to test the feasibility and specificity of diagnostic assays availa-
ble or under development under the conditions of a blood serv-
ice, so that their viability can be assessed at all. Legal certainty 
must be established here about the fact that an information of 
the donors, as well as consequences for the release of blood 
donations or look-back procedures and ultimately the recall of 
donations, may be abandoned if test results are indeterminate. 
This implies to deliberately run the risk of the highly improba-
ble case, which however cannot be completely ruled out, that a 
reactive result is indeed attributable to preclinical vCJD which 
may become conspicuous only after months or even years. 
On account of previously applied technology and technical 
equipment requirements, a longer period of transition is need-
ed before nationwide screening can be implemented, because 
probably methods have to be implemented that have never 
been used routinely in the blood services. This transition period 
will also be necessary to arrange for the required investments, 
computer-based support and quality management/validation of 
the diagnostic assays. 
6.6  Costs
At present no estimation can be made regarding supplementary 
costs for investments, reagents, and personnel required.
6.7  Quality Management
On account of the rareness of the disease, it is not possible at 
present to provide suitable samples for external quality assur-
ance. There are no independent positive or negative controls. 
Thus, it is not possible to compare results of different tests. Ac-
cordingly, a validation by the user is only possible in terms of 
a performance evaluation. Therefore, the establishment of ap-
propriate conditions should be aimed for. For example, every 
diagnostic assay to be implemented should be evaluated with 
an independent panel of human blood samples from patients 
with different TSE isoforms and other neurodegenerative dis-
eases as well as from healthy controls. 
6.8  Safety Considerations 
According to the type of assay selected, safety precautions have 
to be taken that largely prevent hazards for the personnel. This 
applies especially to techniques which potentially generate 
pathological PrPs. In that case in every institution performing 
such tests a BSL-3 laboratory is required with the correspond-
ing investment and maintenance costs. 
6.9  Availability
On implementation of screening tests for prions in blood dona-
tions, it has to be ensured that manufacturing capacities of the 
companies in question are sufficiently large to guarantee an un-
interrupted supply with test kits of consistent quality. The same 
is true for technical support. To interrupt the screening after it 
was implemented because of unavailable test kits would also 
be precarious for ethical reasons. Because different approaches 
will probably be used in the assays, a short-term switch-over to 
instruments and reagents from other manufacturers will be al-
most impossible. 
7 Conclusion and Assessment
The disease vCJD is definitely fatal according to the current 
state of knowledge and is transmissible by blood transfusion. 
To prevent transmission of vCJD by blood transfusion and to 
protect transfusion recipients, the existence of a suitable screen-
ing assay for vCJD in blood donors would be very valuable. 
Still in 2006 the last report of the Working Group came to the 
following conclusion: ‘No such test is currently available nor is 
its availability foreseeable. Providing resources for developing 
suitable test methods should therefore be treated with high pri-
ority’ [2]. This situation has changed in the meantime. 
The detection of the pathological PrPTSE has to be very sensi-
tive and simultaneously specific in a background of physiologi-
cal PrPC present in a concentration that is several magnitudes 
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higher. The amino acid sequence of PrPC is identical to that of 
PrPTSE but is simply folded differently. Therefore, high demands 
are made on the methods. At present there are various far ad-
vanced assays under development, so that it is only a question of 
time when the first screening assays for vCJD will be offered and 
marketed. At present, in accordance with the applicable IVD 
law, it would be rather simple for the manufacturers to obtain 
the CE marking for such assays and thus make them marketable. 
A formal application to the European Commission is required 
in order to include new diagnostic assays into list A (‘high-risk 
products’). Such an application has been filed but might still take 
some time. This process should be emphatically supported.
The mandatory verification and validation of such assays is es-
pecially difficult for technical reasons because suitable vCJD-
positive samples are very scarce. Therefore, it is suggested to 
support the creation of suitable sample panels. Such panels 
should predominantly contain samples from patients with vari-
ous TSE isoforms and with dementia of other etiologies as well 
as from healthy controls. 
Provided that they are technically safe and suitable, IVDs for 
the detection of infections causing severe diseases like vCJD 
have to be employed in assessing the fitness of a blood donor 
in accordance with the TFG. This emphasizes the necessity of 
a performance evaluation study for such novel assays regarding 
their suitability and safety. After successful admission into list 
A of the IVD guideline [54], the performance of the assay must 
be tested in test persons and patients. A precondition for the 
performance evaluation study of an IVD for the detection of 
vCJD infections in blood donors is the informed consent of the 
participants. Participants in a study are entitled at any time to 
learn their test results and would have to receive suitable coun-
seling in case the test was reactive. The ethics boards involved 
are also called upon extensively in designing such studies. The 
main issue is that by a reactive test result a seemingly healthy 
person would be put under suspicion of the imminent outbreak 
of a fatal disease for which the latency is unknown and that can-
not be treated at this point, while confirmation assays to clarify 
this suspected diagnosis are lacking at present. 
Similar ethical problems would result on implementation of 
such assays for routine screening of blood donors. A positive 
test result would imply the obligation of the physician respon-
sible to inform the donor about this fact and to give advice, in 
case the assay was assumed to be reliable and suitable to detect 
a vCJD infection. Already in the case of a ‘justifiable suspicion’ 
that a donor was infected with vCJD, the physician responsi-
ble is obligated to eliminate the donation, to trace and inform 
as well as examine any recipients, and to notify the competent 
authorities, unless there is a reasonable assumption of its prob-
ably being a false-positive result. In the context of this, but also 
regarding the necessary performance evaluation of the diag-
nostic assays, guidelines for the information of donors and re-
cipients have to be developed. On the part of the blood services 
involved, there is an enormous desire for legal security. 
In principle, the current development of screening assays for 
the detection of vCJD is welcome. However, before such assays 
can be marketed and put to routine use, there remain consider-
able problems. In view of the presently known epidemiological 
situation of vCJD in Germany, in view of only four confirmed 
transmissions by blood transfusion in the UK, and in view of 
the difficulties described above regarding performance evalua-
tion, the implementation of vCJD diagnostic assays appears to 
be inadvisable at present.
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